Howard J Levine

US Patent:

6593317, Jul 15, 2003

Filed:

Oct 17, 2000

Appl. No.:

09/833259

Inventors:

Dominique de Ziegler - Paris, FR
William J. Bologna - Paris, FR
Howard L. Levine - Oceanside NY

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A61K 3157

US Classification:

514177, 514899, 5147726, 424487

Abstract:

The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.

US Patent:

6624200, Sep 23, 2003

Filed:

Jun 11, 2001

Appl. No.:

09/877218

Inventors:

William J. Bologna - Paris, FR
Howard L. Levine - Oceanside NY
Dominque DeZiegler - Paris, FR

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A01N 3302

US Classification:

514653, 514649

Abstract:

A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).

US Patent:

6699494, Mar 2, 2004

Filed:

Feb 22, 2000

Appl. No.:

09/510527

Inventors:

Howard L. Levine - Oceanside NY
William J. Bol.ogna - Paris, FR
Dominique De Ziegler - Paris, FR

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A61F 1300

US Classification:

424434, 424422, 424430

Abstract:

The present invention teaches a composition comprising a -adrenergic agonist in a bioadhesive carrier. Preferably, the composition comprises terbutaline in polycarbophil. The present invention additionally teaches the local administration of a -adrenergic agonist for the purpose of treating or preventing dysmenorrhea or premature labor. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events.

US Patent:

6818672, Nov 16, 2004

Filed:

Jul 24, 2002

Appl. No.:

10/089796

Inventors:

William J. Bologna - Paris, FR
Dominique De Ziegler - Paris, FR
Howard L. Levine - Oceanside NY

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A01N 3302

US Classification:

514653, 514654, 514967, 424430, 424433, 424434

Abstract:

The present invention concerns compositions and methods for using a -adrenergic agonist for treating endometriosis, for treating infertility, and for improving fertility. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the -adrenergic agonist locally while avoiding adverse systematic concentrations in the host, thereby minimizing or avoiding adverse side effects.

US Patent:

7153845, Dec 26, 2006

Filed:

Apr 24, 2003

Appl. No.:

10/421840

Inventors:

Howard L. Levine - Oceanside NY, US
William J. Bologna - Paris, FR
Philippe J. Cartier - Paris, FR
Dominique De Ziegler - Geneva, CH

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A61K 31/33
A61K 31/553
A61K 31/554

US Classification:

514183, 51421102

Abstract:

A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).

US Patent:

8425892, Apr 23, 2013

Filed:

Apr 28, 2003

Appl. No.:

10/423920

Inventors:

William J. Bologna - Paris, FR
Howard L. Levine - Oceanside NY, US

Assignee:

Columbia Laboratories, Inc. - Livingston NJ

International Classification:

A61K 31/74

US Classification:

424 781

Abstract:

The present invention relates to a delivery system for pharmaceutical compositions relying in part on an ionic interaction to control and facilitate release of the treating agent. More specifically, the invention relates to an extended controlled-release system having an ionic treating agent and an ionic polymer, wherein the polymer is sufficiently ionized to release the treating agent in a controlled manner over an extended period of time and the composition does not require an emulsion system for administering the treating agent.

US Patent:

20010031747, Oct 18, 2001

Filed:

Apr 3, 2001

Appl. No.:

09/825569

Inventors:

Dominique deZiegler - Paris, FR
William Bologna - Paris, FR
Howard Levine - Oceanside NY, US

Assignee:

COLUMBIA LABORATORIES (BERMUDA) LIMITED - Pembroke

International Classification:

A61K031/57
A61K031/56

US Classification:

514/171000, 514/177000

Abstract:

The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.

US Patent:

20070031491, Feb 8, 2007

Filed:

May 11, 2006

Appl. No.:

11/431611

Inventors:

Howard Levine - Oceanside NY, US
William Bologna - Paris, FR
Dominique De Ziegler - Geneva, CH

International Classification:

A61K 9/22

US Classification:

424468000

Abstract:

A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).